Barriers to inclusion of older adults in randomised controlled clinical trials on Non-Hodgkin's lymphoma: A systematic review

Cancer Treatment Reviews

Volumn 39, Issue 7, 2013, Pages 812-817

  Bellera, Carine ^a,b   Praud, Delphine ^a,b   Petit Monéger, Aurélie ^a,b   McKelvie Sebileau, Pippa ^a   Soubeyran, Pierre ^a,c   Mathoulin Pélissier, Simone ^a,b,c  

^a INSTITUT BERGONIÉ   (France)

^b Centre of Clinical Investigation Clinical Epidemiology   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Aged: aged 80 and over; Clinical trial inclusion; Criteria of eligibility; Frail older; Lymphoma; Non Hodgkin; Randomised controlled trials; Review literature

Indexed keywords

CANCER INCIDENCE; CANCER PATIENT; COMORBIDITY; GERIATRIC ASSESSMENT; GERIATRIC DISORDER; HODGKIN DISEASE; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; PATIENT PARTICIPATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW;

AGED: AGED 80 AND OVER; CLINICAL TRIAL INCLUSION; CRITERIA OF ELIGIBILITY; FRAIL OLDER; LYMPHOMA; NON-HODGKIN; RANDOMISED CONTROLLED TRIALS; REVIEW LITERATURE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LYMPHOMA, NON-HODGKIN; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84881554328     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.01.007     Document Type: Review

References (31)

1. SEER 2005-2009. 2009. http://seer.cancer.gov/statfacts/html/nhl.html.
2. Hiddemann W., Kneba M., Dreyling M., Schmitz N., Lengfelder E., Schmits R., et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106:3725-3732.
3. Marcus R., Imrie K., Solal-Celigny P., Catalano J.V., Dmoszynska A., Raposo J.C., et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008, 26:4579-4586.
4. Monfardini S., Aversa S.M., Zoli V., Salvagno L., Bianco A., Bordonaro R., et al. Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas. Ann Oncol 2005, 16:1352-1358.
5. Soubeyran P., Khaled H., MacKenzie M., Debois M., Fortpied C., de Bock R., et al. Diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma in the frail elderly: a phase II EORTC trial with a progressive and cautious treatment emphasizing geriatric assessment. J Geriatr Oncol 2011, 2:36-44.
6. Lichtman S.M. Clinical trial design in older adults with cancer - the need for new paradigms. J Geriatr Oncol 2012, 3:368-375.
7. Scher K.S., Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol 2012, 30:2036-2038.
8. Hutchins L.F., Unger J.M., Crowley J.J., Coltman C.A., Albain K.S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999, 341:2061-2067.
9. Lewis J.H., Kilgore M.L., Goldman D.P., Trimble E.L., Kaplan R., Montello M.J., et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003, 21:1383-1389.
10. Murthy V.H., Krumholz H.M., Gross C.P. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004, 291:2720-2726.
11. Yee K.W., Pater J.L., Pho L., Zee B., Siu L.L. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier?. J Clin Oncol 2003, 21:1618-1623.
12. Yonemori K., Hirakawa A., Komiyama N., Kouno T., Ando M., Fujiwara Y., et al. Participation of elderly patients in registration trials for oncology drug applications in Japan. Ann Oncol 2010, 21:2112-2118.
13. Aviles A., Nambo M.J., Castaneda C., Cleto S., Neri N., Murillo E., et al. Rituximab and escalated chemotherapy in elderly patients with aggressive diffuse large-cell lymphoma: a controlled clinical trial. Cancer Biother Radiopharm 2007, 22:194-199.
14. Burton C., Linch D., Hoskin P., Milligan D., Dyer M.J., Hancock B., et al. A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma. Br J Cancer 2006, 94:806-813.
15. Chamorey E., Gressin R., Peyrade F., Rossi J.F., Lepeu G., Foussard C., et al. Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma. Oncology 2005, 69:19-26.
16. Foussard C., Colombat P., Maisonneuve H., Berthou C., Gressin R., Rousselet M.C., et al. Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies. Ann Oncol 2005, 16:466-472.
17. Habermann T.M., Weller E.A., Morrison V.A., Gascoyne R.D., Cassileth P.A., Cohn J.B., et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:3121-3127.
18. Merli F., Bertini M., Luminari S., Mozzana R., Botto B., Liberati A.M., et al. Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2007, 48:367-373.
19. Mori M., Kitamura K., Masuda M., Hotta T., Miyazaki T., Miura A.B., et al. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma. Int J Hematol 2005, 81:246-254.
20. Pfreundschuh M., Zwick C., Zeynalova S., Duhrsen U., Pfluger K.H., Vrieling T., et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2008, 19:545-552.
21. Zwick C., Birkmann J., Peter N., Bodenstein H., Fuchs R., Hanel M., et al. Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone). Ann Hematol 2008, 87:717-726.
22. Townsley C.A., Selby R., Siu L.L. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 2005, 23:3112-3124.
23. Talarico L., Chen G., Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004, 22:4626-4631.
24. Dale W., Mohile S.G., Eldadah B.A., Trimble E.L., Schilsky R.L., Cohen H.J., et al. Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. J Natl Cancer Inst 2012, 104:581-589.
25. Kimmick G.G., Peterson B.L., Kornblith A.B., Mandelblatt J., Johnson J.L., Wheeler J., et al. Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001. J Clin Oncol 2005, 23:2201-2207.
26. Kornblith A.B., Kemeny M., Peterson B.L., Wheeler J., Crawford J., Bartlett N., et al. Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer 2002, 95:989-996.
27. Extermann M., Boler I., Reich R.R., Lyman G.H., Brown R.H., DeFelice J., et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2012, 118:3377-3386.
28. Hurria A., Togawa K., Mohile S.G., Owusu C., Klepin H.D., Gross C.P., et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011, 29(25):3457-3465.
29. National Institutes of Health National Cancer Institute Working Group on Enhancing Recruitment to Early Phase Cancer Clinical Trials. Enhancing recruitment to early phase cancer clinical trials: literature review. Bethesda (MD); 2004.
30. Delva F., Marien E., Fonck M., Rainfray M., Demeaux J.L., Moreaud P., et al. Factors influencing general practitioners in the referral of elderly cancer patients. BMC Cancer 2011, 11:5.
31. Bellera C.A., Pulido M., Gourgou S., Collette L., Doussau A., Kramar A., et al. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials. Eur J Cancer 2012, 10.1016/j.ejca.2012.09.035.